Furthermore, such mutations or new ones in the LEP gene may not yet be unraveled due to poor screening; thus, further assessment of LEP and LEPR could reveal new damaging mutations in these genes, useful for clinical testing, prevention, or treatment of various forms of obesity, as well as a better stratification of CRC patients. This evidence concerns the gene LEP and obesity disorder.